Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734625 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Nerve Blocks for Episodic Migraine
A Phase 2 study of Episodic Migraine, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05734625 is a Phase 2 study of Episodic Migraine that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 492-participant average among 13 other Episodic Migraine trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05734625, a Phase 2 study of Episodic Migraine, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine anesthetic (numbing medication) and low dose methylprednisolone (cortisone-like medicine or steroid) work for treating and preventing migraines. Our hypothesis is that the pain of most episodic migraine headaches can be eliminated and prevented for months by blocking the nerves that give pain sensation during a migraine.
Conditions Studied
Interventions
- DRUG Bupivacaine HCl 0.5% Injectable Solution
- DRUG Methylprednisolone 40 MG Injection
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05734625
The ClinicalTrials.gov registry entry for NCT05734625 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 492-participant average among 13 other Episodic Migraine trials with a reported enrollment target (88% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine HCl 0.5% Injectable Solution is the first listed.
NCT05734625 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05734625 about?
NCT05734625 is a clinical study titled "Efficacy of Nerve Blocks for Episodic Migraine". The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine anesthetic (numbing medication) and low dose methylprednisolone (cortisone-like medicine or steroid) work for treating and ...
What is the current status of trial NCT05734625?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-07-10. Estimated completion is 2027-07.
What conditions does trial NCT05734625 study?
This clinical trial studies the following conditions: Episodic Migraine.
What interventions are being tested in trial NCT05734625?
The interventions under investigation include: Bupivacaine HCl 0.5% Injectable Solution (DRUG), Methylprednisolone 40 MG Injection (DRUG).
Who is sponsoring clinical trial NCT05734625?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734625 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Episodic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
RECRUITING · Phase 3
-
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
RECRUITING · Phase 3
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RECRUITING
-
Chiropractic Care for Episodic Migraine
RECRUITING · NA
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.